Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales. The company ...

(Reuters) – The UK’s benchmark FTSE 100 index fell on Wednesday, dragged by healthcare shares after GSK warned of lower annual vaccine sales, while investors awaited the current government’s ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster ... hit by fewer of the shots being given out in the US. The UK’s second-biggest pharmaceutical firm still saw 2% sales growth ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy ... hit by fewer of the shots being given out in the US. The UK’s second-biggest pharmaceutical firm still saw 2% sales growth ...